MedTrace Logo

Prophylactic Ketorolac Post Epiretinal Membrane Surgery

NCT00974753 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-01-13

No results posted yet for this study

Summary

Evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug (NSAID), to prevent macular edema after epiretinal membrane surgery. Patients undergoing epiretinal membrane surgery have increased risk of macular swelling which can adversely affect vision. Since post-intraocular surgery inflammation is a contributing factor to macular swelling and loss of vision, NSAID drops may be able to prevent or minimize the deleterious effects of macular swelling after epiretinal membrane surgery.

Conditions

  • Macular Edema

Interventions

DRUG

Ketorolac 0.5%

Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

OTHER

Saline drops

Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Jeff Gale, MD, FRCSC · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974753 on ClinicalTrials.gov